Skip to content
Moderate

Peptide Law in Colorado

Last reviewed

Status overview

Colorado is a moderate-tier state for compounded peptide access as of August 2026. The April 15 federal reclassification of 12 peptides to an interim evaluation tier provides the legal floor, and the Colorado State Board of Pharmacy adds a registration step: out-of-state compounders must hold a Colorado nonresident registration before shipping into the state.

No peptide-specific law passed in the 2026 Colorado legislative session, which ended May 13. The one compounding bill introduced — Senate Bill 26-066, targeting compounded weight-loss medications — was lost and never reached a floor vote. Colorado therefore enters the post-PCAC period with its pharmacy board framework unchanged, at the moderate tier.

On September 18, 2026, twenty state attorneys general led by Alabama Attorney General Steve Marshall released a letter signed September 17, 2026, asking the Secretary of State and the National Security Council to treat Chinese-sourced ingredients in compounded GLP-1 drugs as a national-security matter; Colorado was not among the signatories. See the explainer and Alabama’s tracker entry.

Regulatory landscape

The Colorado State Board of Pharmacy, housed in the Division of Professions and Occupations (dpo.colorado.gov), regulates compounding under Title 12, Article 280 of the Colorado Revised Statutes and 3 CCR 719-1. Key facts for August 2026:

  • Nonresident prescription drug outlet registration. Out-of-state pharmacies that ship, mail, or deliver drugs into Colorado pursuant to a prescription must register with the board under C.R.S. 12-280-133 before doing business in the state. The same registration framework applies to non-resident 503B outsourcing facilities, which apply through the DPO online services system.
  • Telehealth prescribing. Colorado permits telehealth prescribing of non-controlled substances under standard state practice rules, and peptides under FDA review are not federally scheduled substances, so standard telehealth rules apply. Out-of-state prescribers must hold Colorado licensure before prescribing to Colorado residents.
  • 2026 legislation. SB26-066, introduced in February 2026, would have required compounders of GLP-1 and other weight-loss medications to confirm FDA-grade sourcing, pharmaceutical-grade bulk substances with certificates of analysis, FDA-registered manufacturing, and purity verification, with fines up to $1,000 per dose and Colorado Consumer Protection Act enforcement by the attorney general. The bill died in committee; no similar measure is pending.
  • Patient-specific prescriptions. Compounded peptides require a valid patient-specific prescription under the federal 503A framework. Colorado has not adopted additional bulk-substance restrictions beyond federal requirements.

What the April 15 reclassification and July PCAC vote mean for Colorado

The FDA’s April 15 reclassification does not change Colorado state law directly — but it changes which peptides national compounders are willing to dispense to Colorado residents. At the July 23-24 PCAC meeting, the advisory committee recommended six peptides for the 503A Bulks List: BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, while declining to recommend DSIP. The FDA’s final 503A Bulks List decision remains pending, and additional peptides are already queued for future PCAC review.

The practical effect for Colorado is formulary-driven. National compounders that hold Colorado nonresident registration have narrowed peptide offerings since April, and several have tied availability to the PCAC outcome. Manufacturing capacity for these same peptides is expanding onshore — Vector Science began pharma-grade peptide production in Wisconsin in August — which may ease supply for registered compounders over time.

What this means in practice

  • Prescription path. A valid prescription from a licensed practitioner is required. Telehealth prescribing is accepted for non-controlled substances. Out-of-state prescribers should verify Colorado licensure before prescribing.
  • Compounding pharmacy access. Out-of-state pharmacies must hold current Colorado nonresident registration; check with the compounder before assuming it can ship to Colorado.
  • Lead time. Registration verification commonly adds 7-14 days beyond standard fulfillment timelines.
  • Quality watch. Colorado was among the 14 states that received recalled compounded glutathione from Optimal Balance Pharmacy in August 2026, the same defect that triggered a second Texas recall weeks earlier. Endotoxin testing is a meaningful differentiator when choosing a supplier — the same quality gap ECRI and ISMP flagged for wellness peptides.
  • Post-PCAC outlook. The final 503A Bulks List rulemaking will settle the compounding status of the six recommended peptides. Colorado’s state-level pharmacy board requirements will not change based on the PCAC outcome — federal compounding approval and state pharmacy regulation are distinct frameworks.

Key contacts

  • Colorado State Board of Pharmacy (DPO): dpo.colorado.gov/Pharmacy — verify nonresident registrations, check license status, file complaints.
  • Colorado Medical Board: dpo.colorado.gov/Medical — prescriber verification and telehealth practice rules.
  • Colorado Attorney General: enforces deceptive-trade-practice claims against compounding marketing under the Colorado Consumer Protection Act.

Pharmacy considerations

When a compounding pharmacy serves Colorado, verify that an out-of-state compounder holds a current Colorado nonresident prescription drug outlet registration before placing an order. The state board maintains searchable license records through DPO. For permissive- and moderate-tier states alike, the practical risk is less about state regulation and more about verifying quality controls and post-April-15 formulary status — the same bifurcation between pharma-grade and research-grade supply that state boards are navigating nationwide.

This page was last updated August 26, 2026. State pharmacy regulations change, often without public notice. Verify current requirements with the compounding pharmacy before ordering, and check the PeptidesBeat State Tracker for the latest updates.